Stability evaluation of amoxicillin in a solid premix veterinary formulation by monitoring the degradation products through a new HPLC analytical method

Journal of Pharmaceutical and Biomedical Analysis

Volumn 42, Issue 2, 2006, Pages 192-199

  Perez Lozano P ^a   Garcia Montoya E ^a   Orriols, A ^a   Minarro M ^a   Tico J R ^a   Sune Negre J M ^a  

^a School of Pharmacy UB   (Spain)

Author keywords

Amoxicillin; Degradation products; Liquid chromatography; Pharmaceutical dosage forms; Premix; Stability studies; Validation; Veterinary drug

Indexed keywords

4 HYDROXY DEXTRO PHENYLGLYCINE; ACID; AMOXICILLIN; AMOXICILLIN DERIVATIVE; AMOXICILLIN DIKETOPIPERAZINE; BUFFER; GLYCINE DERIVATIVE; PENICILLOIC ACID; PENILLOIC ACID; UNCLASSIFIED DRUG;

ACCURACY; ANALYTIC METHOD; ARTICLE; DEVICE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG STABILITY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SHELF LIFE; VALIDATION PROCESS;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 33747753861     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2006.04.024     Document Type: Article

References (65)

1. Kowalski P., Oledzka I., and Lamparczyk H. J. Pharm. Biomed. Anal. 32 (2003) 937-947
2. Dousa M., and Hosmanova R. J. Pharm. Biomed. Anal. 37 (2005) 373-377
3. Khedr A., and Darwish I. Bull. Pharm. Sci. 23 (2000) 11-21
4. Doadrio A., Sotelo J.B., Doadrio J.C., Orenga R., and Mayorga A. Eclet. Quim. 19 (1994) 33-47
5. Doadrio A., and Sotelo J. Ann. R. Acad. Farm. 55 (1989) 203-212
6. Mendez R., Alemany M.T., Jurado C., and Martin J. Drug Dev. Ind. Pharm. 15 (1989) 1263-1264
7. Naegele E., and Mortiz R. LC-LG Europe (2005) 38-39
8. Pujol M., Girona V., De Bolos J., Castillo M., and Garcia S. Pharm. Acta Helv. 61 (1986) 51-53
9. Sapena I., Ribas A., Girona V., De Bolos J., Castillo M., and Garcia S. Ann. R. Acad. Farm. 51 (1985) 53-58
10. De Bolos V., Castillo M., and Garcia S. Farm. Ed. Prat. 40 (1985) 237-241
11. Tsuji A., Nakashima E., Hao S., and Yamana T. J. Pharm. Sci. 67 (1978) 1059-1066
12. Canals R., and Caldero J.M. Ciencia Industria Farmaceutica 9 (1977) 230-233
13. Husain S.W., Ghoulipour V., and Sepahrian H. Acta Chromatogr. 14 (2004) 102-109
14. Gunawan Sa., Tan K., and Widjaja S. J. AOAC Int. 83 (2000) 1493-1496
15. Pachali P., Buese E., Treitner A., and Schick W. Pharm. Ind. 54 (1992) 278-286
16. Tico J.R., Dandachi K., Salazar R., and Cemeli J. Ciencia Industria Farmaceutica 7 (1988) 210-216
17. Hendrickx S., Roets E., Hoogmartens J., and Vanderhaeghe H. J. Chromatogr. 291 (1984) 211-218
18. Thangadurai S., Shukla S.K., and Anjaneyulu Y. Anal. Sci. 18 (2002) 97-101
19. a ed. (2005), Ministerio de Sanidad y Consumo, Madrid pp. 832-835
20. a ed. (2005) (2004), Conseil d'Europe, Strasbourg pp. 3659-3661 [Addendum 5]
21. British Pharmacopoeia (2005), The Stationary Office, London pp. 138-141
22. USP 28/NF 23, The United States Pharmacopoeial, 28th Rev., and the National Formulary, 23rd ed., United States Pharmacopoeial Convention, Inc., Rockville, 2005, pp. 143-144.
23. Yongwin Z., Roets E., Bruzzi A., and Smelt A.J.W. J. Liq. Chromatogr. RT 19 (1996) 3305-3314
24. Calagatti de Castro S., and Pedrazzali Jr. J. J. Pharm. Pharm. Sci. 6 (2003) 223-230
25. Suvatna C., and Bruce G C. J. Chromatogr. 615 (1993) 91-96
26. Mascher H.J., and Kikuta C. J. Chromatogr. A 812 (1998) 221-226
27. Menelaou A., Somogyi A.A., Barclay M.L., and Bochner F. J. Chromatogr. B 731 (1999) 261-266
28. Hassan E.E., Darwish I.A., El-khordagui L.K., and Khalil S.A. Alexandria J. Pharm. Sci. 9 (1995) 231-236
29. Muth P., Metz R., Beck H., Bolten W.W., and Vergin H. J. Chromatogr. A 729 (1996) 259-266
30. Yuan Z., Russlie H.Q., and Conafax D.M. J. Chromatogr. B 692 (1997) 361-366
31. Erah P.O., Barrett D.A., and Shaw P.N. J. Chromatogr. B 705 (1998) 63-69
32. El Sayed K.S., Younis M.E., and El-Shanawany A.A. Zagazig J. Pharm. Sci. 7 (1998) 38-47
33. Gau Ch.-S., Chiang Y.-Y., and Hang W.-H. Chin. Pharm. J. 47 (1995) 157-170
34. Tico Grau J.R., Del Pozo Carrascosa A., Salazar Macian R., and Cemeli Pons J. Cir. Farm. 46 (1988) 79-90
35. Meiling Q., Peng W., Yuying S., and Yun W. J. Liq. Chromatogr. RT 26 (2003) 1927-1936
36. Zarapkar S.S., Halkar U.P., and Rane S.H. Indian Drugs 36 (1999) 181-184
37. Zarapkar S.S., Kolter S.S., and Bhandari N.P. Indian Drugs 35 (1998) 107-109
38. Tharakan G., Prakash A., Tyagi S., and Bhatnagar A. Indian Drugs 31 (1994) 382-384
39. De Pourcq P., Hoebus J., Roets E., Hoogmartens J., and Vanderhaeghe H. J. Chromatogr. 321 (1985) 441-449
40. Fong G.W.K., Martin D.T., Johnson R.N., and Kho B.T. J. Chromatogr. 298 (1984) 459-472
41. Muñoz P., Blanca J., Ramos M., Bartolomé M., Garcia E., Méndez N., Gomez J., and Martin de Pozuelo M. Anal. Chim. Acta 529 (2005) 137-144
42. a ed. (2005), Ministerio de Sanidad y Consumo, Madrid pp. 657-658
43. a ed. (2005) (2004), Conseil d'Europe, Strasbourg p. 647 [Addendum 1]
44. British Pharmacopoeia Veterinary (2005), The Stationary Office, London pp. 102-103
45. Patrick J., Mc Donnell, and Blair L. In: Banker G., and Rhodes C. (Eds). Modern Pharmaceutical. 4th ed. (2002), Marcel Dekker, New York 725-733
46. Derrieu G., Raynier B., Ascher F., and Gardey L. Rev. Med. Vet.-Toulouse. 151 (2000) 109-117
47. EMEA/CVMP/VICH/899/99-Rev 1, Guideline on stability testing of new veterinary drug substances and medicinal products, Topic GL3. Draft (deadline for comments January 2006).
48. CVPM/VICH/810/04, Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drugs Substances and New Medical Products, Chemical Substances, VICH Topic GL 39 (released for consultation August 2004).
49. CVMP/VICH/838//99-Rev 1, Quality: impurities in new veterinary medicinal products, VICH Topic GL 11 (Adoption by CVMP for release for new consultation 15 June 2005. End of consultation 1 September 2005).
50. EMEA/CVMP/424/01, Note for guidance on in-use stability testing of veterinary medicinal products (excluding immunological veterinary medicinal products) (CVMP Adopted September 2002).
51. EMEA/CVMP/846/99, Note for guidance on stability testing of existing active substances and related finished products (CVMP Adopted July 2002).
52. CVMP/VICH/900/99, Validation: definitions. Guideline on stability testing of New Veterinary Dosage Forms, VICH Topic GL 4. Step 7 (CVMP approved June 1999).
53. CVMP/VICH/836/99, Stability testing of Medicated Premixes, VICH Topic GL 8. Step 7 (CVPM approved December 1999).
54. USP 28/NF 23, The United States Pharmacopoeia, 28th Rev., and the National Formulary, 23rd ed., United States Pharmacopoeial Convention, Inc., Rockville, 2005, pp. 2748-2751.
55. CVMP/VICH/590/98, Validation: definitions. Guideline on Validation of Analytical Procedures: Definition and Terminology, VICH Topic GL1. Step 7. Consensus guideline (CVMP approved December 1998).
56. CVMP/VICH/591/98, Validation Methodology. Guideline on Validation of Analytical Procedures: Methodology, VICH Topic GL2. Step 7. Consensus Guideline (Approved December 1998).
57. Pérez-Lozano P., García-Montoya E., Orriols A., Miñarro M., Ticó J.R., and Suñe-Negre J.M. J. Pharm. Biomed. Anal. 34 (2004) 979-987
58. Pérez-Lozano P., García-Montoya E., Orriols A., Miñarro M., Ticó J.R., and Suñe-Negre J.M. J. Pharm. Biomed. Anal. 39 (2005) 920-927
59. Validación de métodos analíticos, Monografías AEFI, Girona, Marzo, 2001.
60. Peer Verified Methods Program AOAC, Manual on Policies and Procedures, Arlington, VA, USA, 1993.
61. Zia H., Salchian N., and Borhamian F. Can. J. Pharm. Sci. 12 (1977) 80-83
62. Udupa N., Tatwawadi S.V., and Gode K.D. Indian Drugs 23 (1994) 294-301
63. Traub W.H., and Leonhard B. J. Antimicrob. Chemother. 35 (1995) 149-154
64. De Bolos J., Castillo M., Gallardo M., Girona V., and Riera A. Farm. Ed. Prat. 41 (1986) 255-266
65. Graubels S., De Baere S., and De Backer P. Anal. Chim. Acta 483 (2003) 419-427